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HIV-1 Tat variant are short proteins with variable size and
sequences regarding the HIV-1 subtypes. However a simi-
lar folding is observed among Tat variants with a core
region containing the highly conserved Trp 11. Tat was
first described as an activator of HIV genes. However, Tat
is the only HIV protein to be secreted from HIV infected
cells and has also the capacity to cross cell membranes.
Extra cellular Tat can induce apoptosis to immune cells
and this is certainly essential for the virus in allowing the
survival of HIV infected cells producing viral particles.
This review describes the structure-function relationships
of Tat that should help to develop efficient therapeutical
approaches, particularly a vaccine. A vaccine targeting Tat
could restore the cellular immune response and the elim-
ination of HIV infected cells leading to a curative treat-
ment against AIDS. However, seropositive patients are
unable to develop an efficient humoral response against
Tat and therefore the development of a Tat vaccine have to
take in account this phenomenon with a protein that can
tolerate up to 40% mutations without loss of activity but
changes in its immunogenicity.
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